Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
Maria Paula Diaz Soto,1 Joseph K Lim2 1Department of Medicine, Yale School of Medicine, New Haven, CT, USA; 2Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USACorrespondence: Joseph K LimProfessor of Medicine, Yale Liver Center and Section of Digestive D...
Guardado en:
Autores principales: | Diaz Soto MP, Lim JK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4cb2a65da7ce4a4da3a22e9ab8eb02c3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao YQ, et al.
Publicado: (2016) -
Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar R, et al.
Publicado: (2018) -
Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
por: Alam S, et al.
Publicado: (2018) -
Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus JS, et al.
Publicado: (2021) -
Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta‐analysis
por: Shahinul Alam, et al.
Publicado: (2021)